Home  /  Resource Library  /  Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi

Results of a phase II study of rituximab, lenalidomide, and bendamustine in mantle cell lymphoma.